Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance

Murali, Meena; Kumar, Ayana R; Nair, Bhagyalakshmi; Pavithran, Keechilat; Devan, Aswathy R; Pradeep, Goriparthi; Nath, Lekshmi R

doi:10.1007/s12094-021-02707-5

Cited by 10 publications

(13 citation statements)

References 180 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the cross-linking of B cell receptor for Ag and CD24 has a synergistic effect on apoptosis induction. CD24 is responsible for mediating B cell apoptosis and empowering cancers with immune escape ability by directly inhibiting T cell proliferation ( 26 ).…”

Section: Function Of Cd24 In Immune Systemmentioning

confidence: 99%

“…On microglia, CD24 helps in the proliferation and activation of pathogenic T cells ( 30 ). CD24 also plays a role in facilitating tumor progression by supporting the escape of tumor cells from macrophage-mediated phagocytosis through CD24/Siglec-10 signaling pathway ( 26 ). This provides a nutritional protective shield for the tumor cells.…”

Section: Function Of Cd24 In Immune Systemmentioning

confidence: 99%

See 1 more Smart Citation

Checkpoint CD24 function on tumor and immunotherapy

Huang,

Zhang,

Wei

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

CD24 is a protein found on the surface of cells that plays a crucial role in the proliferation, invasion, and spread of cancer cells. It adheres to cell membranes through glycosylphosphatidylinositol (GPI) and is associated with the prognosis and survival rate of cancer patients. CD24 interacts with the inhibitory receptor Siglec-10 that is present on immune cells like natural killer cells and macrophages, leading to the inhibition of natural killer cell cytotoxicity and macrophage-mediated phagocytosis. This interaction helps tumor cells escape immune detection and attack. Although the use of CD24 as a immune checkpoint receptor target for cancer immunotherapy is still in its early stages, clinical trials have shown promising results. Monoclonal antibodies targeting CD24 have been found to be well-tolerated and safe. Other preclinical studies are exploring the use of chimeric antigen receptor (CAR) T cells, antibody-drug conjugates, and gene therapy to target CD24 and enhance the immune response against tumors. In summary, this review focuses on the role of CD24 in the immune system and provides evidence for CD24 as a promising immune checkpoint for cancer immunotherapy.

show abstract

Section: Function Of Cd24 In Immune Systemmentioning

confidence: 99%

Section: Function Of Cd24 In Immune Systemmentioning

confidence: 99%

Checkpoint CD24 function on tumor and immunotherapy

Huang,

Zhang,

Wei

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Recently, Du et al invented a bispecific antibody targeting the HCC-associated antigen Glypican-3 (GPC3) and CD47, which could inhibit HCC development by enhancing the innate immune response involving macrophages and neutrophils [89] . In addition, blockade of CD47 can increase microenvironmental CD8 + cytotoxic T-cell infiltration as well as enhance tumor cell sensitivity to radiation therapy [90] . Anti-CD47 antibodies combined with T-cell immune checkpoint inhibitors may be an effective therapeutic strategy to achieve stronger antitumor benefits by exploiting the respective advantages.…”

Section: Multifunctional Antibody Against Lcscsmentioning

confidence: 99%

Targeting the interactions between lymphocytes and liver cancer stem cells in combination with immunotherapy is a promising therapeutic strategy

Chen¹,

Zhang²,

Yan³

et al. 2023

Hepatoma Res

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, with a poor prognosis and high recurrence rate. Liver cancer stem cells (LCSCs), a small subset of HCC cells, have the capacity for self-renewal and the property of treatment resistance, suggesting that LCSCs are key factors in causing poor prognosis for HCC patients. In addition, LCSCs interact with immune cells to participate in the formation of an immunosuppressive microenvironment and escape the immune surveillance in HCC, especially lymphocytes. At present, immunotherapies for HCC are mainly based on reactivating the lymphocyte system, including immune checkpoint inhibitors, multifunctional antibodies, and adoptive cell therapy. Therefore, blocking the interactions between lymphocytes and LCSCs in combination with immunotherapy may be a promising therapeutic strategy. This review summarizes the interaction mechanisms of lymphocytes and LCSCs and the current exploration of combination therapy in HCC.

show abstract

“…This has prompted unprecedented enthusiasm for developing ADC drugs as a transformative therapy for solid cancer. There is an increasing number of clinical or preclinical research on ADCs in the field of solid cancer with a rough estimate more than 30 ADCs, 15ADCs, 10 ADCs, 10 ADCs, and 5 ADCs in gastrointestinal malignancies, gynecological malignancies, lung cancer, HER2-positive breast cancer and hepatocellular carcinoma, respectively ( Ferraro et al, 2021 ; Martín-Sabroso et al, 2021 ; Ricciuti et al, 2021 ; Singh et al, 2021 ; Murali et al, 2022 ). Although several reviews have summarized the current state of ADCs in different solid cancers ( Lambert and Morris, 2017 ; Nagayama et al, 2017 ; Deonarain and Yahioglu, 2021 ), a quantitative analysis of publications in this field is scarce.…”

Section: Introductionmentioning

confidence: 99%

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has raised global concern. Although several papers have reviewed the current state of ADCs in different solid cancers, a quantitative analysis of the publications in this field is scarce.Methods: Publications related to ADC in the field of solid cancer were obtained from the Web of Science Core Collection. Data analyses were performed with VOSviewer 1.6.9, HistCite 2.1, CiteSpace V and R package Bibliometrix.Results: A total of 3,482 records were obtained in the holistic field and 1,197 in the clinical field. Steady growth in the number of publications was observed. The United States was the leading contributor in this field. Krop IE was the most influential author. The most productive institution was Genentech Inc., while Mem Sloan Kettering Canc Ctr was the most cited one. The most impactful journal was the Journal of Clinical Oncology. A total of 37 burst references and five burst references were identified between 2017–2022 in the holistic and clinical fields, respectively. Keywords analysis indicated that ADCs research mainly involved breast cancer, triple-negative breast cancer, ovarian cancer, small cell lung cancer, prostate cancer, gastric cancer, and urothelial carcinoma. ADC agents including trastuzumab emtansine, trastuzumab deruxtecan, sacituzumab govitecan, enfortumab vedotin, and rovalpituzumab tesirine were highly studied. Targets including HER2, trophoblast cell-surface antigen, mesothelin, delta-like ligand 3, and nectin-4 were the major concerns.Conclusion: This study analyzed publications concerning ADCs in the field of solid cancer with bibliometric analysis. Further clinical trials of ADCs and designs of the next generation of ADCs are the current focuses of the field. Acquired resistance of ADCs and biomarkers for ADC therapy efficacy monitoring are future concerns.

show abstract

Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance

Cited by 10 publications

References 180 publications

Checkpoint CD24 function on tumor and immunotherapy

Checkpoint CD24 function on tumor and immunotherapy

Targeting the interactions between lymphocytes and liver cancer stem cells in combination with immunotherapy is a promising therapeutic strategy

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Contact Info

Product

Resources

About